Journal of traumatic stressMay 24, 2026

Reevaluating MDMA-assisted therapy for posttraumatic stress disorder

Psychedelic Science Weekly Brief ↗PubMed ↗DOI ↗

Updated May 25, 2026

Abstract

Recent trials indicate encouraging reductions in PTSD symptoms with MDMA-assisted psychotherapy, but significant limitations remain.

Current evidence is constrained by difficulties in blinding and expectancy effects.
There is an absence of robust active comparator conditions in existing studies.
Limited understanding of the mechanisms involved in MDMA-assisted therapy persists.
Concerns exist regarding safety monitoring and the generalizability of sample populations.
The commentary advocates for broader recovery indicators beyond symptom reduction, including quality of life and relational restoration.
Emphasis is placed on the need for equity, scalability, and ethical safeguards in future implementations of MDMA-assisted psychotherapy.

Simplified

In this commentary on Morland et al. (2026)'s recent State of the Science article on 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder (PTSD), we aim to emphasize both MDMA's therapeutic promise and its unresolved scientific challenges. Although recent trials on MDMA-assisted interventions have reported encouraging reductions in PTSD symptoms, the current evidence base remains constrained by several major limitations, including difficulties in blinding, expectancy effects, the absence of robust active comparator conditions, limited mechanistic clarity, and concerns regarding safety monitoring and sample generalizability. This letter argues that these issues are not peripheral but central to the interpretation and future translation of MDMA-assisted psychotherapy. It further highlights the need to move beyond symptom reduction as the primary outcome and incorporate broader indicators of recovery, such as functioning, quality of life, relational restoration, and long-term durability of treatment gains. In addition, we call for stronger attention to equity, scalability, therapist training, and ethical safeguards, particularly if MDMA-assisted psychotherapy is to be considered within a global mental health framework. The discussion aims to stimulate deeper debate on how innovation in trauma treatment should be evaluated before widespread clinical adoption.

Full Text

Full text is available at the source.

View Full Text ↗

Reevaluating MDMA-assisted therapy for posttraumatic stress disorder

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the psychedelic science brief